Calgary, Alberta – July 13, 2021.
For Immediate Release – Medxtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) reports filing of a patent application at the United States Patent and Trademark Office (USPTO).
MedX (CSE: MXT, OTC:MXTTF) reports that it has been notified by it’s patent agent that U.S. Patent Application No. 63/220,004, METHOD OF GENERATING CREDIBLE SOLUTIONS FROM NON-VALIDATED DATASETS, in the name of Medxtractor Corp., has been filed with the USPTO. This application relates to the previously-filed provisional patent filed in late December, 2020 and assigned to the Corporation by its President, James Durward.
ABOUT MEDXTRACTOR CORP:
The Corporation is a Calgary-based company that generates technologically-based solutions. The SHAMAN division is focusing on applying machine learning to predict potential benefits associated with the use of psychedelic drugs within the mental health misdiagnosis problem, and the mHealth division is developing a consumer mHealth applications. With installations all over the world, its legacy craft-scale bio-extractors are used to extract compounds from a variety of botanical materials. Readers are advised that both SHAMAN and the YMI mHealth application require further development and accordingly the Corporation is not currently making any express or implied claims that the applications can, or will be able to, generate accurate results or profits.
FOR FURTHER INFORMATION, PLEASE CONTACT:
James M. Durward, President and CEO
Telephone: (403) 689-3901
Website: www.medxtractor.com or www.shaman-ai.com
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
The post MedXtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) reports filing of a patent application at the United States Patent and Trademark Office (USPTO) appeared first on CannabisFN.psychedelic cse otc regulation laws